Skip to content

Study on prediction of recurrence after chemoradiotherapy for cervical cacner

Multi-institutional prospective study on prediction of out-of-field recurrence after chemoradiotherapy for cervical cancer - JROSG23-5

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1060240139
Enrollment
120
Registered
2025-03-24
Start date
2025-03-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine cervical cancer Uterine crvical cancer, Recurrence, Prediction

Interventions

None listed

Sponsors

Ikushima Hitoshi
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The patient is 18 years or older at the time of the initial visit. Cervical cancer is diagnosed histopathologically and the histological type is either squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. Patients diagnosed as stage IIB or stage III or stage IVA (JSOG 2020, FIGO 2018). Patients who are scheduled to start radical chemoradiotherapy between the date of approval by the Ethics Committee of Tokushima University Hospital and the date of permission by the head of the affiliated institution. Concurrent chemotherapy must be a platinum-containing regimen. Patients undergoing pelvic MRI T2-weighted image and diffusion weighted image within 1 month prior to the start of radiotherapy. Patients to be followed up for 2 years after completion of chemoradiotherapy.

Exclusion criteria

Exclusion criteria: Patients undergoing neoadjuvant chemotherapy prior to radiation therapy. Patients undergoing particle beam therapy as external-beam radiation therapy. Patients who receive prophylactic extended-field irradiation (prophylactic para-aortic lymph node irradiation) as external-beam radiotherapy. However, extended-field irradiation in stage IIIC2 does not meet this exclusion criterion.

Design outcomes

Primary

MeasureTime frame
AUC of ROC analysis with the predicted value of the occurrence of out-of-field recurrence calculated by the multi-radiomic model as the independent variable and out-of-field recurrence as the dependent variable.

Secondary

MeasureTime frame
Sensitivity and specificity at the cutoff value that gives a positive predictive value of 0.9 for the predictive value of the occurrence of out-of-field recurrence calculated by the multi-radiomic model. AUC of ROC analysis with the predicted value of local recurrence/progression calculated by the multi-radiomic model as the independent variable and recurrence/progression as the dependent variable Overall survival Progression-free survival

Contacts

Public ContactHitoshi Ikushima

Tokushima University Graduate School

ikushima@tokushima-u.ac.jp+81-886339051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026